ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

China’s Hepalink Acquires Cytovance

by Jean-François Tremblay
August 31, 2015 | APPEARED IN VOLUME 93, ISSUE 34

China’s Shenzhen Hepalink Pharmaceutical will pay $205 million to acquire the drug actives manufacturer Cytovance Biologics. Cytovance, based in Oklahoma City, says the deal will help it implement a plan to add 5,000-L and 10,000-L mammalian cell reactors as well as 1,000-L and 5,000-L microbial fermentors. Hepalink says the deal aims to boost its international presence. The Chinese firm already owns Scientific Protein Laboratories, a Wisconsin-based heparin producer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment